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polymorphism and breast cancer susceptibility:
An update meta-analysis based on 51 research
studies
Liwa Yu and Jianqiu Chen*Abstract
Background: The association between MHTFR Ala222Val polymorphism and breast cancer (BC) risk are inconclusive.
To derive a more precise estimation of the relationship, a systematic review and meta-analysis was performed.
Methods: A comprehensive search was conducted through researching MEDLINE, EMBASE, PubMed, Web of
Science, Chinese Biomedical Literature database (CBM) and China National Knowledge Infrastructure (CNKI)
databases before August 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to
estimate the strength of the association.
Results: A total of 51 studies including 20,907 cases and 23,905 controls were involved in this meta-analysis.
Overall, significant associations were found between MTHFR Ala222Val polymorphism and BC risk when all studies
pooled into the meta-analysis (Ala/Ala vs Val/Val: OR=0.870, 95%CI=0.789–0.958,P=0.005; Ala/Val vs Val/Val:
OR=0.895, 95%CI=0.821–0.976, P=0.012; dominant model: OR=0.882, 95%CI=0.808–0.963, P=0.005; and recessive
model: OR = 0.944, 95%CI=0.898–0.993, P=0.026; Ala allele vs Val allele: OR = 0.935, 95%CI=0.887–0.986, P=0.013). In
the subgroup analysis by ethnicity, the same results were found in Asian populations, while no significant
associations were found for all comparison models in other Ethnicity populations.
Conclusion: In conclusion, our meta-analysis provides the evidence that MTHFR Ala222Val gene polymorphisms
contributed to the breast cancer development.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1966146911851976
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Breast cancer is the most common cancer and the main
cause of cancer mortality in women. The etiology
towards to this disease is poorly understood, some risk
factors including familial history of the disease, age of
menarche and of menopause, diet, reproductive history,
high estrogen exposure as well as genetic factors may
contribute to its development [1,2]. Studies suggest that
the effect determined by low-penetrance genes, may
provide a plausible explanation for BC susceptibility.* Correspondence: jianqiuchendoctor@163.com
Department of General Surgery, the Secondary Hospital of Tianjin Medical
University, Tianjin 300211, China
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reproduction in any medium, provided the orPolymorphisms in genes are associated with a risk or
protection against the disease. 5,10-methylenetetrahy-
drofolate reductase (MTHFR) is one important genes
located at 1p36.3 [3]. MTHFR Ala222Val polymorphism
has become the most commonly studied one, which has
been considered to influence the enzyme activity of
MTHFR [4]. The MTHFR 222Val/Val (homozygote)
genotype results in 30% enzyme activity in vitro com-
pared with the Ala/Ala wild-type [5]. Numerous epi-
demiological studies have evaluated the association
between the MTHFR Ala222Val polymorphisms and BC
risk. However, these studies have yielded conflicting
results, partially because of the possible small effect ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sample size in each of published studies. The aim of this
study is to derive a more precise estimation of these
associations by performing this meta-analysis.
Materials and methods
Literature search
All studies that examined the association between the
MFTHR Ala222Val polymorphism and BC were identi-
fied. A comprehensive search was conducted through
researching MEDLINE, EMBASE, PubMed, Web of
Science, China Biomedical Literature database (CBM)
and China National Knowledge Infrastructure (CNKI)
databases before August 2012. The search strategy
included the combination of “breast cancer,” “breast
neoplasm,” “methylene-tetrahydrofolate reductase,”
“MTHFR,” “Ala222Val”, “rs1801133”, “variant,” and
“polymorphism.” References of the retrieved articles
were also screened. Non-familial case–control studies
were eligible if they determined the distribution for this
polymorphism in unrelated patients with breast cancer
and in a concurrent control group of healthy subjects
using molecular methods for genotyping. Of the studies
with the same or overlapping data by the same investiga-
tors, we selected the most recent ones with the most
subjects. We evaluated all associated publications to re-
trieve the most eligible literatures. The reference lists of
reviews and retrieved articles were hand searched at the
same time. We did not include abstracts or unpublished
reports. When overlapping data of the same patient
population were included in more than one publication,
only the most recent or complete study was used in this
meta-analysis.
Inclusion and exclusion criteria
The following inclusion criteria were used to select litera-
tures for the meta-analysis: (1) information on the evalu-
ation of MFTHR Ala222Val polymorphism and BC
susceptibility; (2)Only the cohort and case-control studies
were considered;(3) sufficient genotype data were pre-
sented to calculate the OR with 95% CI. Major reasons for
exclusion of studies were: (1) none-case–control studies;
(2) reviews and duplication of the previous publication;
(3) control population including malignant tumor patients;
(4) no usable data reported.
Data extraction
Two investigators reviewed and extracted information
from all eligible publications independently, according to
the inclusion and exclusion criteria listed above. An
agreement was reached by discussion between the two
reviewers whenever there was a conflict. The following
items were collected from each study: first author’s sur-
name, year of publication, ethnicity, total number ofcases and controls with Ala/Ala, Ala/Val, and Val/Val
genotypes, respectively. Different descents were categor-
ized as Caucasians, Asians, and Mixed populations
which included more than one ethnic descent. For case–
control studies, data were extracted separately for each
group whenever possible.
Statistical analysis
The strength of the association between MFHTR
Ala222Val polymorphism and BC risk was measured by
ORs, whereas a sense of the precision of the estimate
was given by 95% Cls. The significance of the summary
OR was determined with a Z-test. We first examined
MFHTR Ala222Val genotypes using co-dominant model
(homogeneous co-dominant model: Ala/Ala vs Val/Val,
heterogeneous co-dominant model: Ala/Val vs Val/Val),
recessive (Ala/Ala vs Ala/Val + Val/Val), and dominant
(Ala/Ala + Ala/Val vs Val/Val) genetic models. Then, the
relationship between the allele and susceptibility to BC
was examined (addictive model: Ala allele vs Val allele).
Stratified analyses were also performed by ethnicities. A
chi-square-based Q-statistic test and an I2-test test were
both performed to evaluate the between-study hetero-
geneity of the studies.
Two models including the fixed-effects model and the
random-effects model of meta-analysis were applied
for dichotomous outcomes. The fixed-effects model
assumes that studies are sampled from populations with
the same effect size, making an adjustment to the study
weights according to the in-study variance. The random-
effects model assumes that studies are taken from popu-
lations with varying effect sizes, calculating the study
weights both from in-study and between-study va-
riances, considering the extent of variation, or hetero-
geneity. A P-value ≥0.10 for the Q-test indicated lack of
heterogeneity among the studies, and so the summary
OR estimate of each study was calculated by the fixed-
effects modelm [6]. Otherwise, the random-effects
model (DerSimonian and Laird method) was used [7]. I2
statistic can be used to quantify heterogeneity irrespect-
ive of the number of studies. The significance of the
pooled OR was determined by the Z-test and P<0.05
was considered as statistically significant. Subgroup ana-
lyses were performed by ethnicity to explore the reasons
of heterogeneity. Sensitivity analyses were performed to
assess the stability of the results. To investigate whether
publication bias might affect the validity of the esti-
mates, funnel plot were constructed. An asymmetric plot
suggests a possible publication bias. Funnel plot asym-
metry was assessed by the method of Egger’s linear
regression test, a linear regression approach to measure
funnel plot asymmetry on the natural logarithm scale of
OR. The significance of the intercept was determined by
the t-test suggested by Egger (P<0.05 was considered
Table 1 The main characteristics of these studies and the distribution of MTHFR Ala222Val genotypes and alleles
among cases and controls
First author [Inference] Year Ethnicity Cases Controls HWE
CC CT TT CC CT TT
Sharp [8] 2002 Caucasian 30 19 5 25 21 11 0.103
Campbell [9] 2002 Caucasian 140 162 33 118 92 23 0.420
Semenza [10] 2003 Caucasian 42 58 5 112 111 24 0.643
Langsenlehner [11] 2003 Caucasian 208 222 64 215 215 65 0.333
Ergul [12] 2003 Caucasian 60 41 17 94 87 12 0.164
Shrubsole [13] 2004 Asian 374 555 183 387 577 196 0.442
Fo¨rsti [14] 2004 Caucasian 134 81 8 181 104 13 0.689
Lee [15] 2004 Asian 58 96 32 50 80 17 0.076
Grieu [16] 2004 Caucasian 166 141 27 242 259 50 0.100
Lin [17] 2004 Asian 43 38 7 173 145 24 0.389
Qi [18] 2004 Asian 42 104 71 59 105 54 0.593
Chen [19] 2005 Mixed 398 476 189 440 509 155 0.689
Kalemi [20] 2005 Caucasian 19 16 7 23 20 8 0.313
Deligezer [21] 2005 Caucasian 98 68 23 128 83 12 0.759
Justenhoven [22] 2005 Caucasian 249 247 61 261 279 93 0.193
Chou [23] 2006 Asian 73 51 18 132 120 33 0.475
Kalyankumar [24] 2006 Caucasian 45 37 6 61 31 3 0.693
Xu [25] 2007 Mixed 398 476 189 440 509 155 0.689
Hekim [26] 2007 Caucasian 22 16 2 38 26 4 0.872
Macis [27] 2007 Caucasian 14 20 12 28 41 11 0.511
Yu [28] 2007 Asian 56 54 9 225 170 25 0.336
Reljic [29] 2007 Caucasian 40 44 9 27 34 4 0.114
Inoue [30] 2008 Asian 239 120 21 393 226 43 0.178
Kotsopoulos [31] 2008 Caucasian 383 421 140 252 341 87 0.087
Suzuki [32] 2008 Asian 150 220 84 338 425 146 0.522
Cheng [33] 2008 Asian 185 133 31 268 221 41 0.624
Langsenlehner [34] 2008 Caucasian 51 43 11 40 48 17 0.685
Ericson [35] 2009 Caucasian 255 235 50 531 452 91 0.707
Gao [36] 2009 Asian 202 305 117 235 301 88 0.592
Ma [37] 2009 Asian 124 183 81 115 188 84 0.663
Platek [38] 2009 Mixed 429 446 119 788 795 219 0.398
Henrı0quez-Herna0ndez [39] 2009 Caucasian 52 65 18 107 138 47 0.823
Cam [40] 2009 Caucasian 48 49 13 47 42 6 0.398
Maruti [41] 2009 Mixed 133 139 46 301 284 62 0.672
Ma [42] 2009 Mixed 225 188 45 222 187 49 0.309
Li [43] 2009 Asian 38 17 10 90 50 3 0.187
Yuan [44] 2009 Asian 16 35 29 32 35 13 0.516
Jin [45] 2009 Asian 18 20 3 49 41 10 0.742
Bentley [46] 2010 Caucasian 346 402 191 429 529 205 0.060
Alshatwi [47] 2010 Asian 34 50 16 36 49 15 0.800
Sangrajrang [48] 2010 Asian 410 144 9 366 110 11 0.427
Weiner [49] 2010 Caucasian 399 364 74 386 326 66 0.808
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NOTE: Weights are from random effects analysis


































































































































































Figure 1 Forest plot of overall breast cancer risk associated with the MTHFR Ala222Val polymorphism (Ala/Ala versus Val/Val).
Table 1 The main characteristics of these studies and the distribution of MTHFR Ala222Val genotypes and alleles
among cases and controls (Continued)
Prasad [50] 2011 Asian 124 5 1 116 8 1 0.062
Batschauer [51] 2011 Caucasian 27 34 7 42 34 9 0.593
Mohammad [52] 2011 Asian 168 53 1 198 37 0 0.190
Naushad [53] 2011 Asian 185 56 3 205 39 0 0.175
Cerne [54] 2011 Caucasian 222 238 62 108 124 37 0.882
Akram [55] 2012 Caucasian 65 25 20 55 45 10 0.855
Barbosa [56] 2012 Mixed 76 83 17 87 70 19 0.389
Lajin [57] 2012 Caucasian 44 52 23 65 48 13 0.359
Jakubowska [58] 2012 Mixed 2032 2166 580 1447 1481 422 0.156
HWE Hardy–Weinberg equilibrium.
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Table 2 Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis
Variables No. of studies Ala/Ala vs Val/Val Ala/Ala vs Ala/Val Ala/Val vs Val/Val
OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P
Total 51 0.870(0.789 0.958) 0.001 0.005 0.969(0.923 1.016) 0.206 0.191 0.895(0.821 0.976) 0.021 0.012
Asian 19 0.787(0.645 0.961) 0.017 0.019 0.929(0.843 1.023) 0.212 0.132 0.865(0.753 0.993) 0.300 0.039
Caucasian 25 0.869(0.741 1.020) 0.040 0.319 1.004(0.921 1.095) 0.137 0.926 0.910(0.778 1.064) 0.031 0.238
Mixed 7 0.925(0.793 1.079) 0.050 0.087 0.958(0.898 1.022) 0.946 0.191 0.912(0.778 1.068) 0.050 0.253
Variables No. of studies Ala/Val + Ala/Val vs Val/Va (dominant) Ala/Ala vs Ala/Val + Val/Va (recessive) Ala allele vs Val allele
OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P
Total 51 0.882(0.808 0.963) 0.004 0.005 0.944(0.898 0.993) 0.055 0.026 0.935(0.887 0.986) 0.000 0.013
Asian 19 0.826(0.703 0.972) 0.075 0.021 0.890(0.799 0.991) 0.043 0.034 0.877(0.801 0.960) 0.003 0.008
Caucasian 25 0.916(0.790 1.063) 0.030 0.247 0.985(0.908 1.069) 0.141 0.720 0.883(0.805 0.968) 0.052 0.359
Mixed 7 0.888(0.758 1.041) 0.029 0.144 0.946(0.890 1.006) 0.773 0.076 0.957(0.838 1.094) 0.000 0.523
Ph: P value of Q-test for heterogeneity test.
NOTE: Weights are from random effects analysis


































































































































































Figure 2 Forest plot of overall breast cancer risk associated with the MTHFR Ala222Val polymorphism (Ala-allele versus Ala-allele).
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Figure 3 Forest plot of a meta-analysis of the association between the MTHFR Ala222Val polymorphism and breast cancer
susceptibility in Asians (Ala/Ala versus Val/Val).
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All statistical tests were performed with Stata (Version




51 eligible studies on MTHFR Ala222Val genotypes and
colorectal cancer were identified through literature search
and selection based on the inclusion and exclusion criteria
[8-58]. The publishing year of the studies was from 2002to 2012. There were 25 studies of Caucasian, 19 studies of
Asians and 7 studies of Mixed populations. In total,
20,907 BC cases and 23,905 controls were included in the
meta-analysis. The selected study characteristics were
summarized in Table 1.
Meta-analysis results
Overall, there was statistically significant difference in BC
risk between the patients with Ala/Ala genotype and those
with Val/Val genotype (OR=0.870, 95%CI=0.789-0.958,
P=0.005; Figure 1). Similarly, significant associations were
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Figure 4 Forest plot of a meta-analysis of the association between the MTHFR Ala222Val polymorphism and breast cancer
susceptibility in Asians (Ala-allele versus Ala-allele).
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95%CI=0.898-0.993, P=0.026; Table 2) and dominant
model comparison (OR=0.882, 95%CI=0.808-0.963,
P=0.005; Table 2). Moreover, we found significant associ-
ation between Ala222Val polymorphism and BC when
examining the contrast of Ala versus Val (OR=0.935, 95%
CI=0.887-0.986, P=0.013; Figure 2). In the stratified analysis
by ethnicity, there was significant association between
Ala222Val polymorphism and BC risk for Ala/Ala vsVal/Val comparison (OR=0.787, 95%CI=0.645-0.961,
P=0.019; Figure 3), recessive model comparison (OR=0.890,
95%CI=0.799-0.991, P=0.034; Table 2), dominant model
comparison (OR=0.826, 95%CI=0.703-0.972, P=0.021;
Table 2) and Ala allele versus Val allele comparison
(OR=0.877, 95%CI=0.801-0.960, P=0.008; Figure 4) among
Asian populations. For Caucasian and Mixed populations,
there was no significant association between Ala222Val
polymorphism and breast cancer risk (Table 2).
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In order to compare the difference and evaluate the sensi-
tivity of the meta-analyses, we conducted one-way sensi-
tivity analysis to evaluate the stability of the meta-analysis.
The statistical significance of the results was not altered
when any single study was omitted, confirming the stabil-
ity of the results. Hence, results of the sensitivity analysis
suggest that the data in this meta-analysis are relatively
stable and credible.
Publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias. The shape of funnel plots did
not reveal any evidence of obvious asymmetry in all
comparison models, and the Egger’s test was used to
provide statistical evidence of funnel plot symmetry. The
results of Begg’s test did not show any evidence of publi-
cation bias.
Discussion
Breast cancer is currently the most frequently occurring
cancer and the leading causes of cancer-related death
among women in the world. Single nucleotide poly-
morphism (SNP) is the most common form of human
genetic variation, and may contribute to individual’s sus-
ceptibility to cancer, however, the underlying molecular
mechanism is unknown. Previous study suggested that
some variants, especially those in the promoter regions
of genes, may affect either the expression or activity
levels of enzymes [59-61] and therefore may be mechan-
istically associated with cancer risk. Previous studies on
the relationship between MTHFR Ala222Val poly-
morphisms and BC risk were contradictory. These in-
consistent results are possibly because of a small effect
of the polymorphism on BC risk or the relatively low
statistical power of the published studies. Hence, the
meta-analysis was needed to provide a quantitative
approach for combining the results of various studies
with the same topic, and for estimating and explaining
their diversity.
Meta analysis has great power for elucidating genetic
factors in cancer. On the bases of the character of cancer,
the effect of one genetic component on the development
of the disease can be easily masked by other genetic and
environmental factors. A meta-analysis potentially investi-
gates a large number of individuals and can estimate the
effect of a genetic factor on the risk of the disease [62,63].
The present study included data from 51 association stud-
ies that had investigated the relationship between the
MTHFR Ala222Val polymorphism and BC.
This present meta-analysis, including 20,907 cases and
23,905 controls, concerned the Ala222Val polymorphism
of MTHFR gene and BC risk. In the meta-analysis,
we found that the variant genotypes of the MTHFRAla222Val polymorphisms were significantly associated
with BC risk. Simultaneously, the same results presented
in stratified analysis by ethnicity. We found that the vari-
ant genotype of the MTHFR Ala222Val polymorphism, in
Asian populations, was associated with significant increase
in BC risk. Although the MTHFR Ala222Val polymorph-
ism may be associated with DNA repair activity, no signifi-
cant association of the variant genotype with BC risk was
found in Caucasian and Mixed populations, suggesting the
influence of the genetic variant may be masked by the
presence of other as-yet unidentified causal genes involved
in colorectal cancer.
Some limitations of this meta-analysis should be
acknowledged. First, our result was based on unadjusted
estimates, while a more precise analysis should be con-
ducted adjusted by other factors like diet habit, smoking,
drinking status, environmental factors and so on.
Second, in the subgroup analyses by ethnicity, relatively
limited study numbers to perform ethnic subgroup ana-
lysis of mixed populations. Moreover, there are no
American and African-American descent populations.
Thus, additional studies are warranted to evaluate the ef-
fect of this functional polymorphism on BC risk in differ-
ent ethnicities, especially in American, African-American
and Mixed populations. In addition, our analysis did not
consider the possibility of gene-gene or SNP-SNP interac-
tions or the possibility of linkage disequilibrium between
polymorphisms.
Despite of some limitations, this meta-analysis provided
evidence of the association between theMTHFR Ala222Val
polymorphisms and BC risk, supporting the hypothesis that
MTHFR Ala222Val polymorphism contributes to overall
BC risk. In subgroup analysis, the same results were found
in Asian populations. In order to verify our findings, well-
designed studies including different ethnic groups with a
careful matching between cases and controls should be
considered in future association studies to confirm the
results from our meta-analysis. Moreover, further evaluat-
ing the effect of gene-gene and gene-environment interac-
tions on the Ala222Val polymorphism and BC risk are
necessary.
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